1Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol, 2001,19: 163-196.
2Furst DE, Wallis R, Broder M, et al. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum,2006,36:159-167.
4Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med ,2001,345 : 1098-1104.
5Rose DN. Benefits of screening for latent Myeobacterium tuberculosis infection. Arch Intern Med, 2000,160 : 1513 - 1521.
6Lichauco JJT, Tankeh-Torres SA, Navarra SV, et al. Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. APLAR J Rheumatol, 2006,9:184-192.
7Araujo Z, de Waard JH, de Larrea CF, et al. The effect of Bacille Calmette-Guerin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis. Vaccine, 2008,26 : 5575 -5581.
8Chan PC, Chang LY, Wu YC, et al. Age-specific cut-offs for the tuberculin skin test to detect latent tuberculosis in BCG-vaccinated children. Int J Tuberc Lung Dis,2008,12 : 1401-1406.
9British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax,2005,60:800-805.
10Salmon D, GTI and AFSSAPS. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine ,2002,69 : 170-172.
3Askling J,Fored CM,Brandt L,et al.Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.Arthritis Rheum,2005,52:1986-1992.
4Tubach F,Salmon D,Ravaud P,et al.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy.Arthritis Rheum,2009,7:1884-1893.
5Dixon WG,Hyrich KL,Watson KD,et al.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy:results from the British society for rheumatology biologics register(BSRBR).2010,69:522-528.
6Saag KG,Teng GG,Patkar NM,et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum,2008,6:762-784.
7Erkens CGM, Kampborst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European- consensus. Eur Respir J, 2010, 36: 925-949.
8Salvana EMT, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Micro Reviews, 2009, 22: 274-290.
9Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis,2010, 69:522-528.
10Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 2003, 3: 148-155.
